Managing insulin resistance: role of liraglutide

Diabetes mellitus is part of the insulin resistance syndrome, which includes hypertension, dyslipidemia, and obesity as its other components. Conversely, insulin resistance is a major pathophysiologic factor in the development of type 2 diabetes. It makes sense, therefore, to choose an anti-diabetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalra, Sanjay, Kalra, Bharti, Kumar, Satish, Sharma, Amit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262368/
https://www.ncbi.nlm.nih.gov/pubmed/22291496
_version_ 1782221714884657152
author Kalra, Sanjay
Kalra, Bharti
Kumar, Satish
Sharma, Amit
author_facet Kalra, Sanjay
Kalra, Bharti
Kumar, Satish
Sharma, Amit
author_sort Kalra, Sanjay
collection PubMed
description Diabetes mellitus is part of the insulin resistance syndrome, which includes hypertension, dyslipidemia, and obesity as its other components. Conversely, insulin resistance is a major pathophysiologic factor in the development of type 2 diabetes. It makes sense, therefore, to choose an anti-diabetic medication that acts on insulin resistance and its clinical components, while having anti-hyperglycemic effects as well. This review discusses the non-glycemic, or extra-pancreatic effects, including insulin sensitization, of liraglutide, a novel GLP-1 analog.
format Online
Article
Text
id pubmed-3262368
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-32623682012-01-30 Managing insulin resistance: role of liraglutide Kalra, Sanjay Kalra, Bharti Kumar, Satish Sharma, Amit Clin Pharmacol Original Research Diabetes mellitus is part of the insulin resistance syndrome, which includes hypertension, dyslipidemia, and obesity as its other components. Conversely, insulin resistance is a major pathophysiologic factor in the development of type 2 diabetes. It makes sense, therefore, to choose an anti-diabetic medication that acts on insulin resistance and its clinical components, while having anti-hyperglycemic effects as well. This review discusses the non-glycemic, or extra-pancreatic effects, including insulin sensitization, of liraglutide, a novel GLP-1 analog. Dove Medical Press 2010-06-24 /pmc/articles/PMC3262368/ /pubmed/22291496 Text en © 2010 Kalra et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Kalra, Sanjay
Kalra, Bharti
Kumar, Satish
Sharma, Amit
Managing insulin resistance: role of liraglutide
title Managing insulin resistance: role of liraglutide
title_full Managing insulin resistance: role of liraglutide
title_fullStr Managing insulin resistance: role of liraglutide
title_full_unstemmed Managing insulin resistance: role of liraglutide
title_short Managing insulin resistance: role of liraglutide
title_sort managing insulin resistance: role of liraglutide
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262368/
https://www.ncbi.nlm.nih.gov/pubmed/22291496
work_keys_str_mv AT kalrasanjay managinginsulinresistanceroleofliraglutide
AT kalrabharti managinginsulinresistanceroleofliraglutide
AT kumarsatish managinginsulinresistanceroleofliraglutide
AT sharmaamit managinginsulinresistanceroleofliraglutide

Ejemplares similares